Celgene Corporation (CELG): Today's Featured Health Care Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Celgene Corporation ( CELG) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day down 2.6%. By the end of trading, Celgene Corporation fell $7.33 (-4.3%) to $161.22 on average volume. Throughout the day, 3,934,080 shares of Celgene Corporation exchanged hands as compared to its average daily volume of 2,777,200 shares. The stock ranged in price between $161.11-$167.38 after having opened the day at $167.00 as compared to the previous trading day's close of $168.55. Other companies within the Health Care sector that declined today were: Atossa Genetics ( ATOS), down 20.3%, Retrophin ( RTRX), down 15.2%, Allied Healthcare Products ( AHPI), down 14.6% and Kips Bay Medical ( KIPS), down 14.3%.

Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Celgene Corporation has a market cap of $70.0 billion and is part of the drugs industry. The company has a P/E ratio of 48.8, above the S&P 500 P/E ratio of 17.7. Shares are down 0.2% year to date as of the close of trading on Thursday. Currently there are 22 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the positive front, BioDelivery Sciences International ( BDSI), up 50.6%, SunLink Health Systems ( SSY), up 40.6%, Mast Therapeutics ( MSTX), up 32.3% and Uroplasty ( UPI), up 28.3%.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Tencent Posts Big Second Quarter Earning Miss as Game Problems Persist

Tencent Posts Big Second Quarter Earning Miss as Game Problems Persist

Stocks Slide, Dollar Rises as China Markets, Lira Crisis Keep Investors Cautious

Stocks Slide, Dollar Rises as China Markets, Lira Crisis Keep Investors Cautious

U.K. Inflation Rises for First Time in 8 Months as Pound Continues to Tumble

U.K. Inflation Rises for First Time in 8 Months as Pound Continues to Tumble

RBS Confirms First Dividend In a Decade After $4.9 Billion DoJ Settlement

RBS Confirms First Dividend In a Decade After $4.9 Billion DoJ Settlement

Tesla's Musk Has Serious Dell Envy; Hedge Funds Reveal Portfolio Changes - ICYMI

Tesla's Musk Has Serious Dell Envy; Hedge Funds Reveal Portfolio Changes - ICYMI